<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390325</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00196</org_study_id>
    <secondary_id>NCI-2009-00196</secondary_id>
    <secondary_id>2006C0050</secondary_id>
    <secondary_id>NCI-7609</secondary_id>
    <secondary_id>CDR0000507441</secondary_id>
    <secondary_id>OSU 06054 / IRB 2006C0050</secondary_id>
    <secondary_id>7609</secondary_id>
    <secondary_id>7609</secondary_id>
    <secondary_id>N01CM00070</secondary_id>
    <secondary_id>N01CM62207</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <nct_id>NCT00390325</nct_id>
    <nct_alias>NCT01645631</nct_alias>
  </id_info>
  <brief_title>Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer</brief_title>
  <official_title>Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well sorafenib tosylate works in treating patients with
      medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to
      the tissue surrounding the thyroid (locally advanced), or has returned after a period of
      improvement (recurrent). Sorafenib tosylate may stop the growth of tumor cells by blocking
      some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess objective response rate of sorafenib tosylate (sorafenib [BAY 43-9006]) in
      metastatic medullary thyroid carcinoma in setting of inherited tumor syndromes, such as
      multiple endocrine neoplasia (MEN) 2A, MEN 2B, or familial medullary thyroid carcinoma
      (FMTC).

      II. To assess objective response rate of sorafenib (BAY 43-9006) in sporadic metastatic
      medullary thyroid carcinoma.

      SECONDARY OBJECTIVES:

      I. To assess toxicity of sorafenib (BAY 43-9006) in patients with metastatic medullary
      thyroid carcinoma.

      II. Measure serum tumor markers calcitonin and carcinoembryonic antigen (CEA) pre-, during,
      and post-treatment to correlate with disease response.

      III. Correlate nuclear medicine functional imaging (fludeoxyglucose F 18 [F-18
      fluorodeoxyglucose] positron emission tomography [PET] scan) data obtained at pre-, during,
      and post-treatment with tumor response.

      IV. Correlate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data obtained at
      pre-, during, and post-treatment with changes in tumor permeability and vascularity with
      tumor response.

      V. Perform pharmacogenomic studies on procured peripheral blood mononuclear cells (PBMCs) if
      clinical responses are observed.

      VI. To correlate between the degree of retrovirus-associated deoxyribonucleic acid (DNA)
      sequences (Ras)-mitogen-activated protein kinase (MAPK) signaling inhibition with vascular
      endothelial growth factor (VEGF) expression in the tumor and clinical response.

      VII. To correlate between the presence and type of ret proto-oncogene (RET) gene defects in
      tumor and clinical response.

      OUTLINE:

      Patients receive sorafenib tosylate orally (PO) twice daily (BID) on days 1-56. Cycles
      repeats every 8 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 5, 2006</start_date>
  <primary_completion_date type="Actual">January 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic Medullary Thyroid Cancer</measure>
    <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
    <description>Measured using MRI scans. Determined using Response Evaluation Criteria in Solid Tumors/World Health Organization response criteria. 95% confidence interval will be calculated to estimate the frequency of response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Decreased Calcitonin Levels</measure>
    <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
    <description>Identifying the number of patients with decreased calcitonin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient With Decreased Carcinoembryonic Antigen (CEA) Levels</measure>
    <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
    <description>Identify the number of patients with decreased Carcinoembryonic Antigen (CEA) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Baseline Dynamic-Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Exchange Rate Constant (Kep)</measure>
    <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
    <description>Median decrease in exchange rate Kep in index lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Ras-MAPK Signaling Inhibition in the Tumor</measure>
    <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
    <description>Identify the number of patients with degree of Ras-MAPK signaling inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Vascular Endothelial Growth Factor (VEGF) Expression in the Tumor</measure>
    <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
    <description>Correlated with clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Uptake Value (SUV Max) as Measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET)</measure>
    <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
    <description>Identify the median SUV at baseline and 8 week follow up as measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Toxicity, Graded Using the Revised National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</measure>
    <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
    <description>Toxicities were graded for patients using the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ret Proto-Oncogene (RET) Gene Defects in the Tumor</measure>
    <time_frame>Baseline</time_frame>
    <description>Percent of patients with RET mutations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selected Polymorphisms of Genes Influencing Sorafenib Tosylate Metabolism and/or Resistance Genes That May Predict Response or Toxicity</measure>
    <time_frame>Baseline</time_frame>
    <description>Changes will be correlated with toxicity and clinical response to therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hereditary Thyroid Gland Medullary Carcinoma</condition>
  <condition>Multiple Endocrine Neoplasia Type 2A</condition>
  <condition>Multiple Endocrine Neoplasia Type 2B</condition>
  <condition>Recurrent Thyroid Gland Medullary Carcinoma</condition>
  <condition>Stage III Thyroid Gland Medullary Carcinoma AJCC v7</condition>
  <condition>Stage IV Thyroid Gland Medullary Carcinoma AJCC v7</condition>
  <condition>Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7</condition>
  <condition>Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7</condition>
  <condition>Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sorafenib tosylate PO BID on days 1-56. Cycles repeats every 8 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>BA4 43 9006</other_name>
    <other_name>BAY 43-9006</other_name>
    <other_name>Bay-439006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib Tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>BAY 43-9006 Tosylate</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>sorafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ELIGIBILITY CRITERIA SPECIFIC FOR ARM A

          -  Histologically confirmed medullary thyroid carcinoma under the clinical setting of
             inherited tumor syndromes, such as multiple endocrine neoplasia (MEN) 2A, MEN 2B, or
             familial medullary thyroid carcinoma (FMTC)

          -  ELIGIBILITY CRITERIA SPECIFIC FOR ARM B

          -  Histologically confirmed medullary thyroid carcinoma under the clinical setting of
             sporadic medullary thyroid carcinoma (MTC)

          -  ELIGIBILITY CRITERIA COMMON FOR ARMS A AND B

          -  Patients must have measurable disease

          -  Metastatic and/or locally advanced or locally recurrent disease

          -  Oral or intravenous (IV) bisphosphonates therapy will be allowed for patients with
             bony metastasis at the investigator's discretion; bisphosphonate usage should be
             recorded if used since these agents may have anti-farnesyl transferase activity and
             may have some therapeutic effect in combination with sorafenib

          -  Life expectancy must be &gt;= six months

          -  Patients must have an Eastern Cooperative Oncology Group performance status 0-2

          -  Leukocytes &gt;= 2,000/uL (10 days prior to patient enrollment)

          -  Absolute neutrophil count &gt;= 1,000/uL (10 days prior to patient enrollment)

          -  Platelets &gt;= 100,000/uL (10 days prior to patient enrollment)

          -  Total bilirubin =&lt; within 2 x upper limit of normal (10 days prior to patient
             enrollment)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; within 3 x upper limit of normal (10 days prior to patient enrollment)

          -  Serum creatinine within normal institutional limits OR creatinine clearance &gt; 30
             mL/min (by Cockcroft-Gault formula) (10 days prior to patient enrollment)

          -  The effects of sorafenib (BAY 43-9006) on the developing human fetus at the
             recommended therapeutic dose are unknown; for this reason and because kinase
             inhibitors are known to be teratogenic, women of child-bearing potential and men must
             agree to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry, for the duration of study participation, and for at
             least 30 days after completion of therapy; should a woman become pregnant or suspect
             she is pregnant while participating in this study, she should inform her treating
             physician immediately (10 days prior to patient enrollment)

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  EXCLUSION CRITERIA FOR ARM A AND B

          -  Patients who have had systemic anti-tumor therapy (such as chemotherapy, biologic
             modifiers or antiangiogenic therapy) within 4 weeks (6 weeks if nitrosourea or
             mitomycin chemotherapy) prior to study entry

          -  Patients who have had external beam radiation therapy within 1 week or if the adverse
             events associated with radiation are not resolved to grade 1 or less prior to study
             entry

          -  Prior therapy with sorafenib (BAY 43-9006), ZD 6474 or AMG-706

          -  Patients currently receiving any other tumor-specific therapy for thyroid cancer or
             investigational therapy; patients receiving adjuvant hormonal therapy for a second
             primary (such as breast cancer or prostate cancer) are allowed to participate as far
             as there are no known drug interactions

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to sorafenib (BAY 43-9006)

          -  Patients unable to swallow sorafenib tablets (e.g. any condition that impairs
             patient's ability to swallow pills)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, uncontrolled hypertension, or psychiatric illness/social situations that
             would limit compliance with study requirements

          -  Patients with any evidence of a bleeding diathesis

          -  Patients actively receiving anticoagulation with therapeutic intent; prophylactic
             anticoagulation (i.e. low dose warfarin) or venous or arterial access devices is
             allowed provided that the prothrombin time (PT), international normalized ratio (INR)
             or partial thromboplastin time (PTT) are normal

          -  Pregnant women or women who are breast-feeding are excluded from this study because
             sorafenib (BAY 43-9006) is an investigational agent and teratogenicity has not been
             evaluated yet; because there is an unknown but potential risk for adverse events in
             nursing infants secondary to treatment of the mother with sorafenib (BAY 43-9006),
             breastfeeding should be discontinued if the mother is treated with sorafenib (BAY
             43-9006)

          -  Human immunodeficiency virus (HIV)-positive patients receiving combination
             anti-retroviral therapy because of possible pharmacokinetic interactions with
             sorafenib (BAY 43-9006); patients with immune deficiency are at increased risk of
             lethal infections when treated with marrow-suppressive therapy

          -  Patients taking the cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin,
             carbamazepine, or phenobarbital), rifampin or St. John's wort due to potential drug
             interactions with sorafenib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhavana Konda</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <results_first_submitted>May 8, 2018</results_first_submitted>
  <results_first_submitted_qc>December 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2018</results_first_posted>
  <last_update_submitted>May 2, 2020</last_update_submitted>
  <last_update_submitted_qc>May 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Medullary</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Multiple Endocrine Neoplasia</mesh_term>
    <mesh_term>Multiple Endocrine Neoplasia Type 2a</mesh_term>
    <mesh_term>Multiple Endocrine Neoplasia Type 2b</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT00390325/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>November 2006 and January 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Hereditary MTC)</title>
          <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Sporadic MTC)</title>
          <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Hereditary MTC)</title>
          <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Sporadic MTC)</title>
          <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonwhite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic Medullary Thyroid Cancer</title>
        <description>Measured using MRI scans. Determined using Response Evaluation Criteria in Solid Tumors/World Health Organization response criteria. 95% confidence interval will be calculated to estimate the frequency of response.</description>
        <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
        <population>1 patient was not evaluable for RECIST evaluation in Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC)</title>
            <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sporadic MTC)</title>
            <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic Medullary Thyroid Cancer</title>
          <description>Measured using MRI scans. Determined using Response Evaluation Criteria in Solid Tumors/World Health Organization response criteria. 95% confidence interval will be calculated to estimate the frequency of response.</description>
          <population>1 patient was not evaluable for RECIST evaluation in Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Decreased Calcitonin Levels</title>
        <description>Identifying the number of patients with decreased calcitonin levels</description>
        <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
        <population>1 patient was not evaluable in Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC)</title>
            <description>Arm A:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sporadic MTC)</title>
            <description>Arm B:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Decreased Calcitonin Levels</title>
          <description>Identifying the number of patients with decreased calcitonin levels</description>
          <population>1 patient was not evaluable in Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient With Decreased Carcinoembryonic Antigen (CEA) Levels</title>
        <description>Identify the number of patients with decreased Carcinoembryonic Antigen (CEA) levels</description>
        <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
        <population>1 patient was not evaluable in Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC)</title>
            <description>Arm A:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sporadic MTC)</title>
            <description>Arm B:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient With Decreased Carcinoembryonic Antigen (CEA) Levels</title>
          <description>Identify the number of patients with decreased Carcinoembryonic Antigen (CEA) levels</description>
          <population>1 patient was not evaluable in Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Baseline Dynamic-Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Exchange Rate Constant (Kep)</title>
        <description>Median decrease in exchange rate Kep in index lesions</description>
        <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
        <population>kep [exchange rate constant]</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC) and Arm B (Sporadic MTC)</title>
            <description>Arm A:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.
Arm B:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Baseline Dynamic-Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Exchange Rate Constant (Kep)</title>
          <description>Median decrease in exchange rate Kep in index lesions</description>
          <population>kep [exchange rate constant]</population>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="25" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Ras-MAPK Signaling Inhibition in the Tumor</title>
        <description>Identify the number of patients with degree of Ras-MAPK signaling inhibition</description>
        <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
        <population>Due to low tumor cellularity in the samples obtained, such evaluation was not possible</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC)</title>
            <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sporadic MTC)</title>
            <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Ras-MAPK Signaling Inhibition in the Tumor</title>
          <description>Identify the number of patients with degree of Ras-MAPK signaling inhibition</description>
          <population>Due to low tumor cellularity in the samples obtained, such evaluation was not possible</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Vascular Endothelial Growth Factor (VEGF) Expression in the Tumor</title>
        <description>Correlated with clinical response.</description>
        <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
        <population>No data available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>MTC in setting of inherited syndromes (MEN-2A, 2B or FMTC) plus Measurable disease Plus No prior ZD6474 or AMG 706</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>MTC in setting of sporadic ds plus Measurable disease Plus No prior ZD6474 or AMG 706</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Vascular Endothelial Growth Factor (VEGF) Expression in the Tumor</title>
          <description>Correlated with clinical response.</description>
          <population>No data available</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Uptake Value (SUV Max) as Measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET)</title>
        <description>Identify the median SUV at baseline and 8 week follow up as measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET).</description>
        <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC) and Arm B (Sporadic MTC)</title>
            <description>Arm A:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.
Arm B:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Uptake Value (SUV Max) as Measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET)</title>
          <description>Identify the median SUV at baseline and 8 week follow up as measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET).</description>
          <units>maximum SUV</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" lower_limit="2.84" upper_limit="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 week follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="2.24" upper_limit="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Toxicity, Graded Using the Revised National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</title>
        <description>Toxicities were graded for patients using the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
        <time_frame>Up to 4 weeks after last dose of sorafenib tosylate</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC) and Arm B (Sporadic MTC)</title>
            <description>Arm A:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.
Arm B:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Toxicity, Graded Using the Revised National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</title>
          <description>Toxicities were graded for patients using the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral cavity pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HFSR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ret Proto-Oncogene (RET) Gene Defects in the Tumor</title>
        <description>Percent of patients with RET mutations</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC)</title>
            <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sporadic MTC)</title>
            <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ret Proto-Oncogene (RET) Gene Defects in the Tumor</title>
          <description>Percent of patients with RET mutations</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Selected Polymorphisms of Genes Influencing Sorafenib Tosylate Metabolism and/or Resistance Genes That May Predict Response or Toxicity</title>
        <description>Changes will be correlated with toxicity and clinical response to therapy.</description>
        <time_frame>Baseline</time_frame>
        <population>Due to low tumor cellularity in the samples obtained, such evaluation was not possible</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Hereditary MTC)</title>
            <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sporadic MTC)</title>
            <description>Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Selected Polymorphisms of Genes Influencing Sorafenib Tosylate Metabolism and/or Resistance Genes That May Predict Response or Toxicity</title>
          <description>Changes will be correlated with toxicity and clinical response to therapy.</description>
          <population>Due to low tumor cellularity in the samples obtained, such evaluation was not possible</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All patients will be evaluable for toxicity from the time of their first treatment with sorafenib (BAY 43-9006) until off study, up to 4 weeks after last dose of sorafenib tosylate&quot;, &quot;through study completion, an average of 1 year.</time_frame>
      <desc>The National Cancer Institutes Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was utilized for adverse event reporting</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Hereditary MTC) and Arm B (Sporadic MTC)</title>
          <description>Arm A:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.
Arm B:
Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Perforation, GI-small bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Infection with normal ANC or Grade 1 or 2 neutrophils-Colon</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/Thrombus/embois</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Taste Changes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oral Cavity Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>LDH</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain or cramping</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Scalp pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HFSR</sub_title>
                <description>hand-foot-skin reaction</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry skin/scalp</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skin lesions/sores</sub_title>
                <description>non HFSR</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Scalp pruritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manisha Shah, MD</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-8629</phone>
      <email>Manisha.Shah@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

